First export distribution agreements signed

The agreements cover the supply of Ergopharm's sterile injectable and oral solid dose products to distributors who hold the appropriate import and wholesale licences in their respective territories. Each partner has been assessed for regulatory standing and storage capability before appointment, and every shipment will be accompanied by a batch-specific Certificate of Analysis and, where a destination requires it, a WHO-type Certificate of a Pharmaceutical Product to support import clearance. Ergopharm supplies on a prescription-only basis and expects its distributors to onward-supply only to licensed pharmacies and clinical customers.

“Every pack we ship leaves Vadodara with a Certificate of Analysis, a serialised identifier and a documented chain of custody, so our distributors and their patients can trust what is inside the carton.”

Product released under these agreements is manufactured in line with GMP and released by a Qualified Person against the Batch Manufacturing Record, with each pack carrying a GS1 DataMatrix code that encodes the product identifier, batch number and expiry date. This serialisation groundwork is intended to give distributors an auditable link between the physical pack and its manufacturing record, and to prepare Ergopharm for the pack-level verification schemes now taking shape in major markets, among them the European framework introduced by the Falsified Medicines Directive and, in the United States, the traceability build-out under the Drug Supply Chain Security Act.

For distributors, the arrangements set out clear responsibilities on both sides. Ergopharm commits to consistent documentation, defined lead times and, for temperature-sensitive lines, cold-chain shipment within the 2 to 8 degrees Celsius range, while partners commit to Good Distribution Practice in storage and onward handling. Shipments are contracted on Incoterms 2020 terms, so responsibility for the goods passes at a defined and mutually understood point in the journey.

The signings open Ergopharm's export register and give the company a defined route to market for its current portfolio, with further territories to be added as additional distributors complete assessment. For patients and prescribers in these markets, the intended outcome is straightforward: medicines that arrive with a complete documentary trail, an intact anti-tampering feature and a serialised pack that can be checked against its record.